
With the continuous improvement of biological detection technology, the scale of biological data is also increasing, which overloads the central-computing server. The use of edge computing in 5G networks can provide higher processing performance for large biological data analysis, reduce bandwidth consumption and improve data security. Appropriate data compression and reading strategy becomes the key technology to implement edge computing. We introduce the column storage strategy into mass spectrum data so that part of the analysis scenario can be completed by edge computing. Data produced by mass spectrometry is a typical biological big data based. A blood sample analysed by mass spectrometry can produce a 10 gigabytes digital file. By introducing the column storage strategy and combining the related prior knowledge of mass spectrometry, the structure of the mass spectrum data is reorganized, and the result file is effectively compressed. Data can be processed immediately near the scientific instrument, reducing the bandwidth requirements and the pressure of the central server. Here, we present Aird-Slice, a mass spectrum data format using the column storage strategy. Aird-Slice reduces volume by 48% compared to vendor files and speeds up the critical computational step of ion chromatography extraction by an average of 116 times over the test dataset. Aird-Slice provides the ability to analyze biological data using an edge computing architecture on 5G networks.
Citation: Miaoshan Lu, Junjie Tong, Weidong Fang, Jinyin Wang, Shaowei An, Ruimin Wang, Hengxuan Jiang, Changbin Yu. Column storage enables edge computation of biological big data on 5G networks[J]. Mathematical Biosciences and Engineering, 2023, 20(9): 17197-17219. doi: 10.3934/mbe.2023766
[1] | Masahiro Seike . Histamine suppresses T helper 17 responses mediated by transforming growth factor-β1 in murine chronic allergic contact dermatitis. AIMS Allergy and Immunology, 2018, 2(4): 180-189. doi: 10.3934/Allergy.2018.4.180 |
[2] | Kamyar Nasiri, Zohreh Mortezania, Sanaz Oftadehbalani, Mohammad Khosousi Sani, Amin Daemi, Seyyedeh Touran Hosseini, Yusuf Döğüş, Zafer Yönden . Parasitology and Covid-19: epidemiological, immunological, pathological, and therapeutic aspects. AIMS Allergy and Immunology, 2023, 7(1): 92-103. doi: 10.3934/Allergy.2023007 |
[3] | Gozde Arslan, Ayla Balci, Rahmi Cubuk, Feyzullah Cetinkaya . Knowledge and experience of radiologists working in Istanbul on radiographic contrast medium anaphylaxis. AIMS Allergy and Immunology, 2017, 1(2): 71-77. doi: 10.3934/Allergy.2017.2.71 |
[4] | Lucie Mondoulet, Sophie Wavrin, Vincent Dioszeghy, Véronique Dhelft, Emilie Puteaux, Mélanie Ligouis, Camille Plaquet, Christophe Dupont, Pierre-Henri Benhamou . No impact of filaggrin deficiency on the efficacy of epicutaneous immunotherapy in a murine model. AIMS Allergy and Immunology, 2017, 1(1): 1-14. doi: 10.3934/Allergy.2017.1.1 |
[5] | Ryuta Muromoto, Kenji Oritani, Tadashi Matsuda . IL-17 signaling is regulated through intrinsic stability control of mRNA during inflammation. AIMS Allergy and Immunology, 2022, 6(3): 188-199. doi: 10.3934/Allergy.2022014 |
[6] | Fuyong Jiao, Yan Pan, JAY N SHAH, Jiale Wang, Kaisheng Xie, Zhilong Mu, Qing Wei . Challenges and management of bleeding in Kawasaki disease with aspirin treatment. AIMS Allergy and Immunology, 2024, 8(4): 324-332. doi: 10.3934/Allergy.2024020 |
[7] | Chunyan Li, Wojciech Dawicki, Xiaobei Zhang, Chris Rudulier, John R. Gordon . IL-10- and retinoic acid-induced regulatory dendritic cells are therapeutically equivalent in mouse models of asthma and food allergy. AIMS Allergy and Immunology, 2021, 5(2): 73-91. doi: 10.3934/Allergy.2021007 |
[8] | Gianna Moscato, Gianni Pala . Occupational allergy to food-derived allergens. AIMS Allergy and Immunology, 2017, 1(1): 21-30. doi: 10.3934/Allergy.2017.1.21 |
[9] | Tamara Tuuminen, Jouni Lohi . Immunological and toxicological effects of bad indoor air to cause Dampness and Mold Hypersensitivity Syndrome. AIMS Allergy and Immunology, 2018, 2(4): 190-204. doi: 10.3934/Allergy.2018.4.190 |
[10] | Swathi Mukurala, Jahanavi Bandla, Swetha kappala . Angioedema-post COVID symptoms. AIMS Allergy and Immunology, 2023, 7(4): 273-280. doi: 10.3934/Allergy.2023018 |
With the continuous improvement of biological detection technology, the scale of biological data is also increasing, which overloads the central-computing server. The use of edge computing in 5G networks can provide higher processing performance for large biological data analysis, reduce bandwidth consumption and improve data security. Appropriate data compression and reading strategy becomes the key technology to implement edge computing. We introduce the column storage strategy into mass spectrum data so that part of the analysis scenario can be completed by edge computing. Data produced by mass spectrometry is a typical biological big data based. A blood sample analysed by mass spectrometry can produce a 10 gigabytes digital file. By introducing the column storage strategy and combining the related prior knowledge of mass spectrometry, the structure of the mass spectrum data is reorganized, and the result file is effectively compressed. Data can be processed immediately near the scientific instrument, reducing the bandwidth requirements and the pressure of the central server. Here, we present Aird-Slice, a mass spectrum data format using the column storage strategy. Aird-Slice reduces volume by 48% compared to vendor files and speeds up the critical computational step of ion chromatography extraction by an average of 116 times over the test dataset. Aird-Slice provides the ability to analyze biological data using an edge computing architecture on 5G networks.
Non-tuberculous mycobacteria (NTM)-induced nodules following botulinum toxin injections are increasingly being reported [1]–[3]. These infections often present as persistent nodules, which can be challenging to diagnose and manage [3]–[5]. This report presents a rare case of Mycobacterium chelonae-induced granulomatous nodules following botulinum toxin injections and includes a comprehensive review of the literature on NTM infections specifically related to botulinum toxin procedures. The aim is to highlight the importance of accurate diagnosis, appropriate antimicrobial therapy, and to provide an overview of reported cases to inform clinical practice.
A 35-year-old healthy male presented with multiple tender and painful nodules localized at injection sites on the forehead and periorbital areas. These nodules appeared three weeks after receiving Onabotulinum toxin injections from an untrusted provider. Initially, the patient was treated with oral steroids by his initial provider without any improvement. On examination, the nodules were tender and erythematous, confined to the injection sites, and no lymphadenopathy was observed (Figure 1a,b). Empiric antibiotic therapy with oral ciprofloxacin 500 mg twice daily and clindamycin 900 mg daily was initiated to cover potential bacterial infections. However, there was no improvement after three days of treatment. A biopsy was performed on the largest nodule. The specimen was sent for histopathology to rule out mycobacterial infection or sarcoidosis. Additional samples were sent for mycobacterial, bacterial, and fungal cultures, along with NTM PCR testing. Histopathological analysis revealed interstitial granulomatous inflammation with mild necrosis, indicative of a suppurative granuloma (Figure 1c). NTM PCR confirmed the presence of Mycobacterium chelonae. Antimicrobial susceptibility testing was performed, showing no resistance. Based on the diagnosis of NTM-induced granulomatous nodules, the patient was started on a combination therapy of oral clarithromycin 500 mg, levofloxacin 500 mg, and trimethoprim/sulfamethoxazole 160 mg/800 mg, all administered twice daily for six months. Significant improvement was noted six weeks into the therapy, with total remission observed at four months. At an eight-month follow-up, the patient showed no signs of relapse.
A comprehensive review of the literature identified eight reported cases of botulinum toxin-induced granulomatous nodules attributed to NTM infection. The key characteristics of these cases are summarized in Table 1.
The eight cases involved female patients with a mean age of 38 years. Six cases were associated with botulinum toxin injections for wrinkle treatment, while two cases were related to injections for masseter hypertrophy. The nodules typically appeared an average of 20 days post-injection and were characterized by painful, erythematous, and violaceous lesions, with some cases progressing to abscess formation [1]–[7].
Of the eight cases, six underwent biopsy, which revealed suppurative granulomas [1]–[4],[6],[7]. In the remaining two cases, a biopsy was not performed due to positive culture results [1],[2]. All isolated organisms were identified as NTM. Specifically, five cases were caused by Mycobacterium abscessus [2]–[5], one case by Mycobacterium immunogenum [7], and one case was culture and PCR-negative but treated empirically based on strong clinical and histological suspicion [6]. One case presented with acid-fast positive bacilli on histology, but the specific NTM species was not identified [1]. Notably, nodules caused by M. abscessus appeared between 4 to 10 days post-injection, while the nodule due to M. immunogenum emerged 3.5 months after the procedure [2]–[5],[7].
To date, no previous cases of M. chelonae associated with botulinum toxin-induced granulomatous nodules have been reported in the literature. The identification of this organism in our case thus represents the first documented instance of M. chelonae as an etiological agent in such a context.
Study | Age & Sex | Toxin Source | Clinical Presentation | Histology | Organism | Treatment | Outcome |
Li et al. | 39/F | NA | Painful nodules at injection sites 1 week later | Necrotic granuloma | M. abscessus (PCR) | Levofloxacin 500 mg BID, clarithromycin 500 mg BID (stopped in 1 week), surgical excision | NA |
Thanasarnaksorn et al. | 42/F | Neuronox® | Tender nodules at all sites of injection 4 days later | Suppurative granuloma | Negative culture and PCR for NTM | Clarithromycin 500 mg/day, levofloxacin 500 mg/day for 6 months (empirically) | Major improvement at 6 weeks, full resolution at 6 months |
Deng et al. | 53/F | NA | Painful nodules and abscesses at injection sites 10 days later | Suppurative granuloma | M. abscessus (culture) | Amikacin 200 mg, clarithromycin 500 mg, moxifloxacin 400 mg for 7 months | Full resolution after 7 months |
Chen et al. | 32/F | Non-trusted source | Painful papules and nodules on all injection sites 1 week later | Suppurative granuloma | M. abscessus (culture) | Prednisone 30 mg/d, intravenous azithromycin, clarithromycin 250 mg BID, rifampicin 450 mg daily, ethambutol 250 mg TID for 3 months | Full resolution after 3 months with atrophic scars and PIH |
Chen et al. | 34/F | Non-trusted source | Painful papules and nodules on lower jaw, malar, and temple region 10 days later | Biopsy not done | M. abscessus (culture) | Intralesional corticosteroids, oral penicillin, gentamicin, debridement, clarithromycin 250 mg BID, rifampicin 450 mg daily for nearly 6 months | Full resolution after 6 months with scarring and PIH |
Yeon et al. | 34/F | Unknown source | Tender nodule over the left mandible after 3.5 months | Suppurative granuloma | M. immunogenum (culture) | Phenoxymethylpenicillin, clindamycin, clarithromycin 500 mg BID for 6 months | Full resolution |
Saeb-Lima et al. | 45/F | NA | Tender nodules at points of injection 1 week later | Suppurative granuloma with acid-fast positive bacilli | Culture not done | Rifampicin, clarithromycin, azithromycin for 40 days | Full resolution with PIH |
Ou et al. | 25/F | Unknown source | Painful nodules on cheeks 10 days later | Biopsy not done | M. abscessus (culture) | Azithromycin for 2 weeks, surgical excision, clarithromycin 300 mg for 6 months | Full resolution with dog-ear deformity after excision |
In patients presenting with nodules after botulinum toxin injections, initial management can include oral antibiotics and topical treatments [8],[9]. It is crucial to avoid starting oral steroids empirically due to the high risk of infectious nodules compared to non-infectious ones. Biopsy remains the gold standard for determining the etiology of the nodule. If the nodule is found to be inflammatory, such as in sarcoidal nodules, systemic steroids along with immunosuppressive agents may be administered [8],[10]–[14]. However, if the histology shows suppurative or necrotic features, NTM infection should be ruled out using special stains, cultures, and PCR [9].
For infectious granulomas with positive NTM PCR or culture results, treatment should be tailored according to antibiotic sensitivity profiles. Since M. abscessus is the most frequently isolated organism and is known for its rapid growth and high resistance rates, combination therapy involving at least two antimicrobial agents is recommended for a duration of 4 to 6 months. Preferred treatments include a macrolide, such as clarithromycin, paired with agents like amikacin, levofloxacin, cefoxitin or tigecycline [15]–[17].
In the single case involving M. immunogenum, successful treatment was achieved with clarithromycin 500 mg twice daily for six months [7]. Antimicrobial therapy alone led to complete remission in five cases, though post-inflammatory hyperpigmentation (PIH) was noted in three instances [1],[2]. When antimicrobial therapy proved insufficient, surgical excision or debridement was performed in three cases, despite the higher risk of scarring associated with these procedures [2],[4],[5].
Given that negative cultures and PCR results are not uncommon in NTM infections, it is crucial to consider NTM infection as a potential cause of suppurative granulomas with negative test results. For cases with strong clinical and histological suspicion, multiple specimens should be tested through culture and PCR if initial tests are negative. Alternatively, empirical treatment can be initiated based on clinical and histological findings [15],[16]. This approach was exemplified by Thanasarnaksorn et al., who achieved full remission with a six-month regimen of clarithromycin and levofloxacin despite initial negative test results [6].
This case, along with the review of the literature on NTM infections following botulinum toxin injections, underscores the necessity for clinicians to consider NTM infections in patients presenting with persistent nodules post-procedure, particularly when initial treatments fail. This is the first reported case of M. chelonae as the etiological agent in such a context. To prevent such infections, it is crucial for patients to seek treatment from trusted and licensed providers who use authentic products and perform procedures in sterile environments.
The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.
[1] |
H. Lin, S. Garg, J. Hu, X. Wang, M. J. Piran, M. S. Hossain, Privacy-enhanced data fusion for COVID-19 applications in intelligent internet of medical things, IEEE Int. Things J., 8 (2020), 15683–15693. https://doi.org/10.1109/JIOT.2020.3033129 doi: 10.1109/JIOT.2020.3033129
![]() |
[2] |
W. Fang, C. Zhu, W. Zhang, Toward secure and lightweight data transmission for cloud-edge-terminal collaboration in artificial intelligence of things, IEEE Int. Things J., (2023). https://doi.org/10.1109/JIOT.2023.3295438 doi: 10.1109/JIOT.2023.3295438
![]() |
[3] |
W. Fang, C. Zhu, F. R. Yu, K. Wang, W. Zhang, A secure data aggregation strategy in edge computing and blockchain empowered internet of things, IEEE Trans. Ind. Inform., 18 (2022), 4265-4274. https://doi.org/10.1109/TII.2021.3122370 doi: 10.1109/TII.2021.3122370
![]() |
[4] | D. Abadi, S. Madden, M. Ferreira, Integrating compression and execution in column-oriented database systems, in Proceedings of the 2006 ACM SIGMOD international conference on Management of data, (2006), 671–682. https://doi.org/10.1145/1142473.1142548 |
[5] | D. J. Abadi, Column stores for wide and sparse data, in CIDR 2007 - 3rd Biennial Conference on Innovative Data Systems Research, (2007), 292–297. |
[6] | D. J. Abadi, S. R. Madden, N. Hachem, Column-stores vs. row-stores: How different are they really?, in Proceedings of the 2008 ACM SIGMOD International Conference on Management of Data, (2008), 967–980. https://doi.org/10.1145/1376616.1376712 |
[7] |
K. Cao, Y. Liu, G. Meng, Q. Sun, An overview on edge computing research, IEEE Access, 8 (2020), 85714–85728. https://doi.org/10.1109/ACCESS.2020.2991734 doi: 10.1109/ACCESS.2020.2991734
![]() |
[8] |
Y. Ai, M. Peng, K. Zhang, Edge computing technologies for Internet of Things: a primer, Digital Commun. Netw., 4 (2018), 77–86. https://doi.org/10.1016/j.dcan.2017.07.001 doi: 10.1016/j.dcan.2017.07.001
![]() |
[9] |
N. Hulstaert, J. Shofstahl, T. Sachsenberg, M. Walzer, H. Barsnes, L. Martens, et al., ThermoRawFileParser: Modular, scalable, and cross-platform RAW file conversion, J. Proteome Res., 19 (2020), 537–542. https://doi.org/10.1021/acs.jproteome.9b00328 doi: 10.1021/acs.jproteome.9b00328
![]() |
[10] |
E. W. Deutsch, File formats commonly used in mass spectrometry proteomics, Mol. Cell. Proteomics, 11 (2012), 1612–1621. https://doi.org/10.1074/mcp.R112.019695 doi: 10.1074/mcp.R112.019695
![]() |
[11] |
H. S. Wiley, G. S. Michaels, Should software hold data hostage?, Nat. Biotechnol., 22 (2004), 1037–1038. https://doi.org/10.1038/nbt0804-1037 doi: 10.1038/nbt0804-1037
![]() |
[12] |
L. Martens, A. I. Nesvizhskii, H. Hermjakob, M. Adamski, G. S. Omenn, J. Vandekerckhove, et al., Do we want our data raw? Including binary mass spectrometry data in public proteomics data repositories, Proteomics, 5 (2005), 3501-3505. https://doi.org/10.1002/pmic.200401302 doi: 10.1002/pmic.200401302
![]() |
[13] |
G. Mayer, L. Montecchi-Palazzi, D. Ovelleiro, A. R. Jones, P. A. Binz, E. W. Deutsch, et al., The HUPO proteomics standards initiativemass spectrometry controlled vocabulary, Database, 2013 (2013). https://doi.org/10.1093/database/bat009 doi: 10.1093/database/bat009
![]() |
[14] |
P. G. A. Pedrioli, J. K. Eng, R. Hubley, M. Vogelzang, E. W. Deutsch, B. Raught, et al., A common open representation of mass spectrometry data and its application to proteomics research, Nat. Biotechnol., 22 (2004), 3501-3505. https://doi.org/10.1038/nbt1031 doi: 10.1038/nbt1031
![]() |
[15] |
L. Martens, M. Chambers, M. Sturm, D. Kessner, F. Levander, J. Shofstahl, et al., mzML—a Community Standard for Mass Spectrometry Data, Mol. Cell. Proteomics, 10 (2011). https://doi.org/10.1074/mcp.R110.000133 doi: 10.1074/mcp.R110.000133
![]() |
[16] |
E. W. Deutsch, N. Bandeira, V. Sharma, Y. Perez-Riverol, J. J. Carver, D. J. Kundu, et al., The ProteomeXchange consortium in 2020: Enabling 'big data' approaches in proteomics, Nucleic Acids Res., 48 (2020), D1145–D1152. https://doi.org/10.1093/nar/gkz984 doi: 10.1093/nar/gkz984
![]() |
[17] |
E. W. Deutsch, N. Bandeira, Y. Perez-Riverol, V. Sharma, J. J. Carver, L. Mendoza, et al., The ProteomeXchange consortium at 10 years: 2023 update, Nucleic Acids Res., 51 (2023), D1539–D1548. https://doi.org/10.1093/nar/gkac1040 doi: 10.1093/nar/gkac1040
![]() |
[18] |
N. S. Kale, K. Haug, P. Conesa, K. Jayseelan, P. Moreno, P. Rocca‐Serra, et al., MetaboLights: An open-access database repository for metabolomics data, Current Protoc. Bioinformatics, 2016 (2016). https://doi.org/10.1002/0471250953.bi1413s53 doi: 10.1002/0471250953.bi1413s53
![]() |
[19] |
K. Haug, K. Cochrane, V. C. Nainala, M. Williams, J. Chang, K. V. Jayaseelan, et al., MetaboLights: An open-access database repository for metabolomics data, Nucleic Acids Res., 48 (2020), D440–D444. https://doi.org/10.1093/nar/gkz1019 doi: 10.1093/nar/gkz1019
![]() |
[20] |
M. Wilhelm, M. Kirchner, J. A. J. Steen, H. Steen, mz5: Space- and time-efficient storage of mass spectrometry data sets, Mol. Cell. Proteomics, 11 (2012). https://doi.org/10.1074/mcp.O111.011379 doi: 10.1074/mcp.O111.011379
![]() |
[21] | M. Folk, G. Heber, Q. Koziol, E. Pourmal, D. Robinson, An overview of the HDF5 technology suite and its applications, in Proceedings of the EDBT/ICDT 2011 Workshop on Array Databases, (2011), 36–47. https://doi.org/10.1145/1966895.1966900 |
[22] |
J. Teleman, A. W. Dowsey, F. F. Gonzalez-Galarza, S. Perkins, B. Pratt, H. L. Röst, et al., Numerical compression schemes for proteomics mass spectrometry data, Mol. Cell. Proteomics, 13 (2014), 1537–1542. https://doi.org/10.1074/mcp.O114.037879 doi: 10.1074/mcp.O114.037879
![]() |
[23] |
D. Bouyssié, M. Dubois, S. Nasso, A. G. de Peredo, O. Burlet-Schiltz, R. Aebersold, et al., MzDB: A file format using multiple indexing strategies for the efficient analysis of large LC-MS/MS and SWATH-MS data sets, Mol. Cell. Proteomics, 14 (2015), 771–781. https://doi.org/10.1074/mcp.O114.039115 doi: 10.1074/mcp.O114.039115
![]() |
[24] | T. Bhosale, T. Patil, P. Patil, SQLite: Light Database System, in Int. J. Comput. Sci. Mob. Comput., 44 (2015), 882–885. |
[25] |
R. Yang, X. Chen, I. Ochoa, MassComp, a lossless compressor for mass spectrometry data, BMC Bioinformatics, 20 (2019). https://doi.org/10.1186/s12859-019-2962-7 doi: 10.1186/s12859-019-2962-7
![]() |
[26] |
B. Tully, Toffee–a highly efficient, lossless file format for DIA-MS, Sci. Rep., 10 (2020). https://doi.org/10.1038/s41598-020-65015-y doi: 10.1038/s41598-020-65015-y
![]() |
[27] |
R. S. Bhamber, A. Jankevics, E. W. Deutsch, A. R. Jones, A. W. Dowsey, MzMLb: A future-proof raw mass spectrometry data format based on standards-compliant mzML and optimized for speed and storage requirements, J. Proteome Res., 20 (2021), 172–183. https://doi.org/10.1021/acs.jproteome.0c00192 doi: 10.1021/acs.jproteome.0c00192
![]() |
[28] |
F. Hanau, H. Röst, I. Ochoa, mspack: efficient lossless and lossy mass spectrometry data compression, Bioinformatics, 37 (2021), 3923–3925. https://doi.org/10.1093/bioinformatics/btab636 doi: 10.1093/bioinformatics/btab636
![]() |
[29] |
M. Lu, S. An, R. Wang, J. Wang, C. Yu, Aird: a computation-oriented mass spectrometry data format enables a higher compression ratio and less decoding time, BMC Bioinformatics, 23 (2022). https://doi.org/10.1186/s12859-021-04490-0 doi: 10.1186/s12859-021-04490-0
![]() |
[30] |
J. Wang, M. Lu, R. Wang, S. An, C. Xie, C. Yu, StackZDPD: A novel encoding scheme for mass spectrometry data optimized for speed and compression ratio, BMC Bioinformatics, 12 (2022), 5384. https://doi.org/10.1038/s41598-022-09432-1 doi: 10.1038/s41598-022-09432-1
![]() |
[31] |
M. Lu, J. Tong, R. Wang, S. An, J. Wang, C. Yu, Aird-ComboComp: A combinable compressor framework with a dynamic-decider for lossy mass spectrometry data compression, bioRxiv, 2023 (2023). https://doi.org/10.1101/2023.05.04.539411 doi: 10.1101/2023.05.04.539411
![]() |
[32] |
R. Schmid, S. Heuckeroth, A. Korf, A. Smirnov, O. Myers, T. S. Dyrlund, et al., Integrative analysis of multimodal mass spectrometry data in MZmine 3, Nat. Biotechnol., 41 (2023), 447–449. https://doi.org/10.1038/S41587-023-01690-2 doi: 10.1038/S41587-023-01690-2
![]() |
[33] |
D. Lemire, L. Boytsov, N. Kurz, SIMD compression and the intersection of sorted integers, Software Pract. Exper., 46 (2016), 723–749. https://doi.org/10.1002/spe.2326 doi: 10.1002/spe.2326
![]() |
[34] | Google, Zstd, 1.5.2, (2022). Available from: https://github.com/facebook/zstd |
[35] | Google, snappy, 1.1.9, (2022). Available from: https://github.com/google/snappy |
[36] |
J. Alakuijala, A. Farruggia, P. Ferragina, E. Kliuchnikov, R. Obryk, Z. Szabadka, et al., Brotli: A general-purpose data compressor, ACM Trans. Inf. Syst., 37 (2018), 1–30. https://doi.org/10.1145/3231935 doi: 10.1145/3231935
![]() |
[37] |
J. Tong, M. Lu, B. Peng, S. An, J. Wang, C. Yu, How much storage precision can be lost: Guidance for near-lossless compression of untargeted metabolomics mass spectrometry data, bioRxiv, (2023). https://doi.org/10.1101/2023.03.14.532504 doi: 10.1101/2023.03.14.532504
![]() |
[38] | R. Adusumilli, P. Mallick, Data conversion with proteoWizard msConvert, in Methods in Molecular Biology, Humana Press, (2017), 339–368. https://doi.org/10.1007/978-1-4939-6747-6_23 |
1. | Robert J. Hill, Radoslaw Trojanek, An evaluation of competing methods for constructing house price indexes: The case of Warsaw, 2022, 120, 02648377, 106226, 10.1016/j.landusepol.2022.106226 | |
2. | Junhao Zhong, Zhenzhen Wang, Artificial intelligence techniques for financial distress prediction, 2022, 7, 2473-6988, 20891, 10.3934/math.20221145 | |
3. | 2023, 1813-9450, 10.1596/1813-9450-10301 | |
4. | Min Shu, Ruiqiang Song, Detection of financial bubbles using a log-periodic power law singularity (LPPLS) model, 2024, 1556-5068, 10.2139/ssrn.4734944 | |
5. | Radoslaw Trojanek, Michal Gluszak, Justyna Tanas, Alex van de Minne, Detecting housing bubble in Poland: Investigation into two housing booms, 2023, 140, 01973975, 102928, 10.1016/j.habitatint.2023.102928 | |
6. | Sandro Heiniger, Winfried Koeniger, Michael Lechner, The heterogeneous response of real estate prices during the Covid-19 pandemic, 2024, 0964-1998, 10.1093/jrsssa/qnae078 | |
7. | Michał Hebdzyński, Are Hedonic Models Really Quality-Adjusted? The Role of Apartment Quality in Hedonic Models of Housing Rental Market, 2024, 32, 2300-5289, 46, 10.2478/remav-2024-0014 | |
8. | Min Shu, Ruiqiang Song, Detection of financial bubbles using a log‐periodic power law singularity (LPPLS) model, 2024, 16, 1939-5108, 10.1002/wics.1649 | |
9. | Michał Hebdzyński, Quality information gaps in housing listings: Do words mean the same as pictures?, 2023, 38, 1566-4910, 2399, 10.1007/s10901-023-10043-z | |
10. | Roland Füss, Kathleen Kürschner Rauck, Alois Weigand, Housing Price Externalities of Photovoltaic Systems: The Relevance of View, 2023, 1556-5068, 10.2139/ssrn.4618784 |
Study | Age & Sex | Toxin Source | Clinical Presentation | Histology | Organism | Treatment | Outcome |
Li et al. | 39/F | NA | Painful nodules at injection sites 1 week later | Necrotic granuloma | M. abscessus (PCR) | Levofloxacin 500 mg BID, clarithromycin 500 mg BID (stopped in 1 week), surgical excision | NA |
Thanasarnaksorn et al. | 42/F | Neuronox® | Tender nodules at all sites of injection 4 days later | Suppurative granuloma | Negative culture and PCR for NTM | Clarithromycin 500 mg/day, levofloxacin 500 mg/day for 6 months (empirically) | Major improvement at 6 weeks, full resolution at 6 months |
Deng et al. | 53/F | NA | Painful nodules and abscesses at injection sites 10 days later | Suppurative granuloma | M. abscessus (culture) | Amikacin 200 mg, clarithromycin 500 mg, moxifloxacin 400 mg for 7 months | Full resolution after 7 months |
Chen et al. | 32/F | Non-trusted source | Painful papules and nodules on all injection sites 1 week later | Suppurative granuloma | M. abscessus (culture) | Prednisone 30 mg/d, intravenous azithromycin, clarithromycin 250 mg BID, rifampicin 450 mg daily, ethambutol 250 mg TID for 3 months | Full resolution after 3 months with atrophic scars and PIH |
Chen et al. | 34/F | Non-trusted source | Painful papules and nodules on lower jaw, malar, and temple region 10 days later | Biopsy not done | M. abscessus (culture) | Intralesional corticosteroids, oral penicillin, gentamicin, debridement, clarithromycin 250 mg BID, rifampicin 450 mg daily for nearly 6 months | Full resolution after 6 months with scarring and PIH |
Yeon et al. | 34/F | Unknown source | Tender nodule over the left mandible after 3.5 months | Suppurative granuloma | M. immunogenum (culture) | Phenoxymethylpenicillin, clindamycin, clarithromycin 500 mg BID for 6 months | Full resolution |
Saeb-Lima et al. | 45/F | NA | Tender nodules at points of injection 1 week later | Suppurative granuloma with acid-fast positive bacilli | Culture not done | Rifampicin, clarithromycin, azithromycin for 40 days | Full resolution with PIH |
Ou et al. | 25/F | Unknown source | Painful nodules on cheeks 10 days later | Biopsy not done | M. abscessus (culture) | Azithromycin for 2 weeks, surgical excision, clarithromycin 300 mg for 6 months | Full resolution with dog-ear deformity after excision |
Study | Age & Sex | Toxin Source | Clinical Presentation | Histology | Organism | Treatment | Outcome |
Li et al. | 39/F | NA | Painful nodules at injection sites 1 week later | Necrotic granuloma | M. abscessus (PCR) | Levofloxacin 500 mg BID, clarithromycin 500 mg BID (stopped in 1 week), surgical excision | NA |
Thanasarnaksorn et al. | 42/F | Neuronox® | Tender nodules at all sites of injection 4 days later | Suppurative granuloma | Negative culture and PCR for NTM | Clarithromycin 500 mg/day, levofloxacin 500 mg/day for 6 months (empirically) | Major improvement at 6 weeks, full resolution at 6 months |
Deng et al. | 53/F | NA | Painful nodules and abscesses at injection sites 10 days later | Suppurative granuloma | M. abscessus (culture) | Amikacin 200 mg, clarithromycin 500 mg, moxifloxacin 400 mg for 7 months | Full resolution after 7 months |
Chen et al. | 32/F | Non-trusted source | Painful papules and nodules on all injection sites 1 week later | Suppurative granuloma | M. abscessus (culture) | Prednisone 30 mg/d, intravenous azithromycin, clarithromycin 250 mg BID, rifampicin 450 mg daily, ethambutol 250 mg TID for 3 months | Full resolution after 3 months with atrophic scars and PIH |
Chen et al. | 34/F | Non-trusted source | Painful papules and nodules on lower jaw, malar, and temple region 10 days later | Biopsy not done | M. abscessus (culture) | Intralesional corticosteroids, oral penicillin, gentamicin, debridement, clarithromycin 250 mg BID, rifampicin 450 mg daily for nearly 6 months | Full resolution after 6 months with scarring and PIH |
Yeon et al. | 34/F | Unknown source | Tender nodule over the left mandible after 3.5 months | Suppurative granuloma | M. immunogenum (culture) | Phenoxymethylpenicillin, clindamycin, clarithromycin 500 mg BID for 6 months | Full resolution |
Saeb-Lima et al. | 45/F | NA | Tender nodules at points of injection 1 week later | Suppurative granuloma with acid-fast positive bacilli | Culture not done | Rifampicin, clarithromycin, azithromycin for 40 days | Full resolution with PIH |
Ou et al. | 25/F | Unknown source | Painful nodules on cheeks 10 days later | Biopsy not done | M. abscessus (culture) | Azithromycin for 2 weeks, surgical excision, clarithromycin 300 mg for 6 months | Full resolution with dog-ear deformity after excision |